Generate Biomedicines, INC

8-K10-Q

Market Movers (8-K)

NASDAQ
GENB
Generate Biomedicines, INC
8-K: Generate Biomedicines Reports Q3 2026 Results, Advances Pipeline
Generate Biomedicines announced third quarter 2026 financial results, highlighting progress in severe asthma and COPD drug candidates, new collaborations, and a cash runway into early 2028.
Capital raise
Worse than expected

Quarterly Earnings (10-Q)

NASDAQ
GENB
Generate Biomedicines, INC
10-Q: Generate Biomedicines Faces Cash Crunch Despite IPO
Generate Biomedicines reported a net loss of $216.6 million for the first nine months of 2026, with cash reserves expected to last into mid-2028, highlighting ongoing capital requirements.
Capital raise
Worse than expected